在Capivasertib治疗期间通过持续的葡萄糖监测识别的特征性血糖模式:一个案例报告
Hironori Takahashi1, Satoko Hatayama1, Tomohito Izumi1
1Division of Diabetes and Metabolism, Sendai City Hospital, Japan.
Internal medicine (Tokyo, Japan)
|December 17, 2025
概括
AKT抑制剂capivasertib可以在乳腺癌患者中引起显著的高血糖症. 这种葡萄糖失调,标志着白天的尖峰,当治疗停止时会消失,需要仔细监测患者.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 复发性乳腺癌带来了重大的治疗挑战.
- AKT 抑制剂是治疗晚期癌症的新兴疗法.
- 针对性治疗的代谢副作用需要进行表征.
研究的目的:
- 报告与capivasertib治疗相关的高血糖病例.
- 在接受AKT抑制剂的患者中描述血糖特征.
- 为了研究卡皮瓦塞尔蒂布诱导高血糖的潜在机制.
主要方法:
- 持续的葡萄糖监测 (CGM) 用于跟踪葡萄糖水平.
- 评估了患者对静脉输血葡萄糖的血糖反应.
- 评估了甲福明对高血糖症的影响.
- 在治疗期间和无药时间间隔内比较葡萄糖概况.
主要成果:
- 患者患有明显的白天食后高血糖症和夜间到早上的下降.
- 超血糖在无药时间间隔内消失.
- 甲胺在控制高血糖症方面无效.
- 静脉注射葡萄糖输液加剧了高血糖症.
结论:
- 由于AKT抑制,capivasertib诱导的高血糖症可能是由于葡萄糖吸收受损和肝脏葡萄糖输出失调的结果.
- 持续的葡萄糖监测对于识别特定的血糖模式至关重要.
- 个性化的血糖管理策略对于服用AKT抑制剂的患者至关重要.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562
Glucose Absorption Into the Small Intestine
34.7K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
34.7K
Insulin: Dosing Regimen and Adverse Effects
656
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
656
Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
Glucose Homeostasis: Regulation of Blood Glucose
3.7K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.7K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
505
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
505


